Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 17/20 | 0.49 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6508603 | 1.00 | CALCRL (0.49) | CALCRLRAMP1CHRM1CHRM2CHRM4 | |
| SCHEMBL6506530 | 0.98 | CALCRL (0.47) | CALCRLRAMP1CHRM1CHRM2CHRM4 | |
| SCHEMBL6506537 | 0.98 | CALCRL (0.47) | CALCRLRAMP1CHRM1CHRM2CHRM4 | |
| SCHEMBL6510349 | 0.95 | CALCRL (0.43) | CALCRLRAMP1CHRM1 | |
| SCHEMBL6503455 | 0.94 | CALCRL (0.45) | CALCRLRAMP1CHRM1CYP3A4 | |
| SCHEMBL13313781 | 0.94 | CALCRL (0.42) | CALCRLRAMP1CHRM1CHRM2CHRM4 | |
| SCHEMBL3309604 | 0.89 | CALCRL (0.63) | CALCRLRAMP1CHRM1 | |
| SCHEMBL3309597 | 0.89 | CALCRL (0.63) | CALCRLRAMP1CHRM1 | |
| SCHEMBL2165100 | 0.88 | CALCRL (0.42) | CALCRLRAMP1CHRM1CHRM2CHRM4 | |
| SCHEMBL2165094 | 0.88 | CALCRL (0.42) | CALCRLRAMP1CHRM1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250763-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250763-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 46/4885CHRM1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.